Feed

ADAP

Adaptimmune Therapeutics plc

ADAP · NASDAQ

$0.05 +8.07% (+$0.00)

Piotroski F-Score Weak

0/9

Valuation

N/A

P/FCF N/A

P/E N/A

EV/FFO N/A

Growth

N/A

FCF growth N/A

EPS growth N/A

Book val. growth N/A

Profitability

N/A

Op. margin N/A

Gross margin N/A

FCF margin N/A

Quality

N/A

ROA N/A

ROIC N/A

Asset turnover N/A

Debt

N/A

Debt/Assets N/A

Debt/Equity N/A

Net debt/EBITDA N/A

Stability

0 /100

Unstable

Beta 2.49x

Profitable years N/A

Rev. volatility N/A

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ADAP

Online

About the company

Adaptimmune Therapeutics plc (ADAP) is a biotechnology company focused on the development and commercialization of immunotherapeutic drugs for cancer treatment. The company specializes in developing T-cell receptors (TCRs) and genetically modified T-cells (CAR-T) for therapeutic use in various types of tumors. Adaptimmune aims to create personalized therapeutic approaches that harness the patient's own immune system to fight cancer. With a successful portfolio of clinical studies and a focus on innovation in cancer therapy, shares of Adaptimmune Therapeutics plc (ADAP) may be suitable for investors seeking opportunities in the biotechnology sector with an emphasis on innovative cancer treatments.

Sector

Healthcare

Industry

Biotechnology

CEO

Adrian G. Rawcliffe

Employees

506

Headquarters

Abingdon

⌘ K

StockBot Live

Market situation Wall Street

Wall Street slides as Treasury yields near 5%

The S&P 500 fell -0.21% and the Dow -0.44%. Rising Treasury yields near 5% erased earlier tech-driven gains.

Ask about this

StockBot knows 80,000+ stocks worldwide